[HTML][HTML] Drug repurposing approach to fight COVID-19

TU Singh, S Parida, MC Lingaraju, M Kesavan… - Pharmacological …, 2020 - Springer
Currently, there are no treatment options available for the deadly contagious disease,
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …

[HTML][HTML] Translating IL-6 biology into effective treatments

EH Choy, F De Benedetti, T Takeuchi… - Nature Reviews …, 2020 - nature.com
Abstract In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is
important for antibody production by B cells. Since its discovery more than 40 years ago, the …

[HTML][HTML] Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis

C Deng, Q Zhang, P He, B Zhou, K He, X Sun… - Nature …, 2021 - nature.com
Insufficient apoptosis of inflammatory macrophages and osteoclasts (OCs) in rheumatoid
arthritis (RA) joints contributes toward the persistent progression of joint inflammation and …

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

PM Villiger, S Adler, S Kuchen, F Wermelinger, D Dan… - The Lancet, 2016 - thelancet.com
Background Giant cell arteritis is an immune-mediated disease of medium and large-sized
arteries that affects mostly people older than 50 years of age. Treatment with glucocorticoids …

Tocilizumab (actemra)

M Sheppard, F Laskou, PP Stapleton… - Human vaccines & …, 2017 - Taylor & Francis
Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R)
monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic …

Adverse effects of biologics: a network meta‐analysis and Cochrane overview

JA Singh, GA Wells, R Christensen… - Cochrane database …, 2011 - cochranelibrary.com
Background Biologics are used for the treatment of rheumatoid arthritis and many other
conditions. While the efficacy of biologics has been established, there is uncertainty …

Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases

S Siebert, A Tsoukas, J Robertson, I McInnes - Pharmacological reviews, 2015 - ASPET
The human immune system involves highly complex and coordinated processes in which
small proteins named cytokines play a key role. Cytokines have been implicated in the …

[HTML][HTML] Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study

WJ Lee, ST Lee, J Moon, JS Sunwoo, JI Byun, JA Lim… - …, 2016 - Elsevier
A considerable portion of autoimmune encephalitis (AE) does not respond to conventional
immunotherapies and subsequently has poor outcomes. We aimed to determine the efficacy …

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

CR Holroyd, R Seth, M Bukhari, A Malaviya… - …, 2019 - academic.oup.com
Christopher R. Holroyd1, Rakhi Seth1, Marwan Bukhari2, Anshuman Malaviya3, Claire
Holmes1, Elizabeth Curtis4, Christopher Chan1, Mohammed A. Yusuf3, Anna Litwic4, 5 …

[HTML][HTML] Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases

T Tanaka, T Kishimoto - International journal of biological sciences, 2012 - ncbi.nlm.nih.gov
Abstract Interleukin (IL)-6, a cytokine featuring redundancy and pleiotropic activity,
contributes to host defense against acute environmental stress, while dysregulated …